Cellectis shares fall on pivot to in vivo gene editing
Cellectis said it is pivoting away from its legacy cell therapy pipeline to focus entirely on its in vivo gene editing business; shares were down 27% to $2.25 in premarket.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.